Healthcare Media & Clinician Networks · B2C Consumer App / Platform
Hims & Hers
Consumer telehealth platform with subscription-based treatment and fulfilment.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Hims & Hers Health, Inc.
- Entity type
- COMPANY
- Founded
- 2017
- Headquarters
- 2261 Market Street, Suite 483, San Francisco, CA 94114
- Company size
- 1,001–5,000
- Market cluster / sector
- Healthcare Media & Clinician Networks
- Market role
- B2C Consumer App / Platform
- Ticker
- HIMS
- Official website
- hims.com
What Hims & Hers does
Hims & Hers operates a vertically integrated digital healthcare marketplace and service platform for consumers. It acquires demand through branded consumer channels, routes users through digital intake and licensed-provider review, converts eligible users into prescription or treatment plans, and captures downstream value through pharmacy fulfilment, recurring medication delivery, and ongoing care management. The model creates value by reducing friction in access to routine and sensitive care categories, while increasing lifetime value through subscriptions, cross-sell into adjacent conditions, and improved treatment matching supported by proprietary clinical interaction data.
Category differentiation
Hims & Hers is a consumer telehealth and prescription fulfilment platform, not a pure SaaS vendor or a general hospital provider. Its AI capability supports internal clinical workflows rather than functioning as a standalone foundation model business.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Hims & Hers Health, Inc. is a publicly listed consumer health company operating a direct-to-consumer telehealth platform. It connects patients with licensed healthcare providers through a digital workflow covering intake, consultation, prescribing, fulfilment, home delivery, and ongoing follow-up. Its core offers span sexual health, mental health, dermatology, weight management, hormone therapy, diagnostics, and women’s health. The business serves consumers directly under the Hims and Hers brands and uses its proprietary MedMatch system internally to support treatment matching and care personalisation. The company generates revenue primarily from recurring subscription care plans that bundle consultations, prescriptions, medication delivery, and ongoing treatment management. Additional revenue comes from one-off purchases, diagnostics, and category expansion into higher-value treatments such as weight loss and hormone health. Its strategic model is built around vertical integration, proprietary data from platform interactions, and geographic expansion beyond the United States through acquisitions and launches in Europe and Canada, with broader international ambitions stated by management.
Company news briefing
Briefing updated:
Hims & Hers continues to prioritise international expansion through the Zava acquisition and corporate restructuring, though recent financial filings indicate ongoing shifts in profitability. Regulatory and legal pressures have intensified following an FTC lawsuit and subsequent securities class action alleging the unanalysed sharing of sensitive customer health data with major advertising platforms. Meanwhile, strong consumer adherence to prescription product formulations like the Biotin + Minoxidil gummy supports robust full-year revenue guidance between $2.8 billion and $3 billion.
Business model & monetisation
Hims & Hers monetises primarily through recurring consumer subscriptions tied to treatment plans, prescription medications, and ongoing access to care. It also captures revenue from consultation-related services, one-off product purchases, diagnostics, and prescription fulfilment. Commercially, the model blends subscription billing, service fees embedded in care pathways, and product margin on delivered pharmaceuticals and wellness treatments. Growth is reinforced by upsell across multiple condition categories and expansion into higher-value speciality treatments.
- Recurring treatment subscriptions
- Subscription billing for ongoing care, prescriptions, and delivery
- Prescription fulfilment and medication sales
- Retail margin on pharmaceuticals and wellness products
- Consultation and care access
- Service fee embedded in telehealth visits and treatment workflows
- Diagnostics and testing
- One-time sale or episodic service revenue
Products & capabilities
No products with linked sources are available in this view.
Unlock Full Intelligence Profile for Hims & Hers
Get unlimited access to corporate ownership, historical M&A transactions, verified tech stack telemetry, and live market signals in the interactive Knowledge Graph.
Verified Ownership & Corporate Hierarchy
Complete corporate hierarchy traversal, shareholder cap table history, and parent holding links sourced from regulatory filings.
360° Tech Stack & Vendor Telemetry
Technical header bidding configurations, sellers.json registry nodes, CMP disclosures, and direct programmatic supply chains.
Live Market Signals & Executive Briefings
Continuous 24/7 monitoring of material M&A deals, executive shifts, product rollouts, and hiring trends across peer entities.
Competitors & alternatives
Track competitor shifts
Receive automated telemetry on strategic moves, acquisitions, and market share shifts across Hims & Hers's competitive landscape.
Consumer health media and engagement platform with B2B health solutions.
Saudi pharmacy retailer with omnichannel commerce and clinic services.
Digital health publisher with healthcare advertising and audience targeting assets.
Ambulatory healthcare software for EHR, billing and patient engagement.
Integrated health benefits, care delivery and healthcare analytics company.
Side-by-side comparisons
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
Hims & Hers Securities Class Action Deadline Nov 2, 2026
Privacy · Recorded impact score: 3/5
Robbins Geller Rudman & Dowd LLP has announced a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS), alleging violations of the Securities Exchange Act. The lawsuit, captioned Velanki v. Hims & Hers Health, Inc., is pending in the Northern District of California. It claims that the company made false statements and failed to disclose that it shared consumers' sensitive health information with third-party advertising platforms like Meta and Snap, and that it misled consumers about billing practices. Following an FTC lawsuit filed on July 29, 2026, the company's stock dropped nearly 15%. Investors who purchased securities between August 4, 2025 and July 29, 2026 have until November 2, 2026, to seek lead plaintiff appointment under the Private Securities Litigation Reform Act.
- FTC filed a lawsuit against Hims & Hers on July 29, 2026, alleging sharing of sensitive health data with advertising platforms like Meta and Snap, and misleading billing.
- Hims & Hers stock declined nearly 15% following the FTC announcement.
8-K Financial Filing Analysis for Hims & Hers (2026-10-07)
financials · Recorded impact score: 2.8/5
Hims & Hers Health, Inc. announced the appointment of Jonathan M. Franklin as Chief Accounting Officer and Principal Accounting Officer, effective October 9, 2026. Mr. Franklin succeeds Irene Becklund, who previously resigned but will remain with the company in an advisory capacity through July 10, 2027, ensuring an orderly transition. Prior to joining Hims & Hers, Franklin served as Vice President, Corporate Controller at Rivian Automotive and spent over 15 years in public accounting at PwC. His compensation package includes an annual base salary of $425,000, a $150,000 signing bonus, an annual target bonus of 50%, and an initial grant of $3,000,000 in restricted stock units (RSUs) vesting over four years.
- Jonathan M. Franklin appointed Chief Accounting Officer and Principal Accounting Officer effective October 9, 2026, succeeding Irene Becklund.
- Compensation includes an annual base salary of $425,000, a $150,000 signing bonus, a 50% target discretionary bonus, and $3,000,000 in equity awards (RSUs) vesting over 4 years.
Hims & Hers Securities Fraud Class Action Filed
Privacy · Recorded impact score: 2/5
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) in the U.S. District Court for the Northern District of California. The suit alleges the telehealth company disclosed sensitive health information to third-party advertising platforms, including Snap and Meta (Facebook), without proper consent, and misled consumers about billing practices. The FTC filed a related lawsuit on July 29, 2026, causing the stock to drop 14.73% to $25.00. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to apply as lead plaintiff. The case, Velanki v. Hims & Hers Health, Inc. et al., is being publicized by law firms including Kahn Swick & Foti, Kessler Topaz Meltzer & Check, and the Law Offices of Howard G. Smith.
- FTC sued Hims & Hers for sharing sensitive health data with advertising platforms (Snap, Meta) and deceptive billing practices.
- Hims & Hers stock dropped $4.32 (14.73%) to $25.00 on July 29, 2026.
10-Q Financial Filing Analysis for Hims & Hers (2026-08-10)
financials · Recorded impact score: 4.5/5
Hims & Hers reported Q2 2026 revenue of $753.2 million, up 38% year-over-year, and six-month revenue of $1.36 billion (+20% YoY), driven by strong expansion in the Hers brand and international growth from acquisitions including Eucalyptus. However, the company experienced a GAAP net loss of $86.3 million for Q2 2026 (compared to net income of $42.5 million in Q2 2025), primarily impacted by a strategic transition in its U.S. GLP-1 weight loss business, non-recurring restructuring charges, increased fulfillment costs from shorter shipping cadences, and a $60 million FTC legal contingency accrual.
- Q2 2026 total revenue reached $753.21 million (+38% YoY) with ending subscribers expanding 19% YoY to 2.89 million.
- GAAP net loss was $86.29 million for Q2 2026, down from net income of $42.51 million in Q2 2025, while Adjusted EBITDA stood at $60.32 million.
Explore company relationships
Questions about Hims & Hers
What is Hims & Hers?
Hims & Hers is a public consumer telehealth platform that connects patients with licensed providers and delivers prescription treatments, diagnostics, and ongoing subscription care.
Who uses Hims & Hers?
Individual consumers use Hims & Hers for discreet, convenient access to online consultations, prescription medications, weight management, mental health, dermatology, hormone health, and related care.
How does Hims & Hers make money?
It makes money mainly from recurring subscriptions, prescription fulfilment, medication sales, consultation-related services, diagnostics, and cross-sell across treatment categories.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
13 publicly documented primary sources and citations linked across the market graph.
Continue your research on Hims & Hers
Open additional company details, personal Watchlists and your Strategic Intelligence Agent in Polaris7. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Daily intelligent monitoring · Verified primary sources.
Unlock full intelligence profile, ownership & live market signals